Oncolys Biopharma Inc. (4588)

Overview

Oncolys BioPharma Inc. is a pivotal player in the biopharmaceutical sector, focusing on the discovery, development, manufacture, and distribution of innovative therapies and diagnostic tools for cancer treatment. Established in 2004 with its headquarters in Tokyo, Japan, the company extends its reach across Japan, various other Asian countries, and the United States. It leverages cutting-edge research in oncolytic viruses, drugs, and tumor diagnostic agents aiming to redefine cancer care. Among its strategic endeavors, Oncolys BioPharma Inc. has entered into several vital licensing agreements with prestigious institutions and corporations, including Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc., to bolster its product development and market presence.

Products and Services

• Telomelysin (OBP-301): A groundbreaking oncolytic adenovirus currently in phase II clinical trials for the treatment of gastric cancer/gastroesophageal junction, head and neck, and esophageal cancers, and in phase I for hepatocellular carcinoma. It represents a novel approach in directly targeting and destroying cancer cells.
• OBP-702: Another telomerase-specific oncolytic adenovirus, at the pre-clinical trial phase, designed for the treatment of solid tumors. It highlights Oncolys BioPharma Inc.'s commitment to expanding its oncolytic virus-based therapies.
• OBP-2011: This is at the pre-clinical trial stage for tackling the SARS-Cov-2 virus infection, showcasing the company's versatility in responding to global health threats beyond cancer.
• OBP-601 (Censavudine): A nucleotide reverse transcriptase inhibitor that has sailed through phase IIb clinical trials for combating HIV infection, underscoring the company’s breadth in addressing viral infections alongside its cancer-centric endeavors.
• OBP-801: Positioned in phase I clinical trial for the treatment of solid tumors and pre-clinical trial for ophthalmic uses, this histone deacetylase inhibitor signifies the company's investment in developing versatile therapeutics for a range of conditions.
• TelomeScan (OBP-401 and OBP-1101): Developed as a cancer detection drug, it is aimed at identifying living circulating tumor cells in the blood of cancer patients, reflecting Oncolys BioPharma Inc.'s commitment to enhancing the diagnostics landscape for early cancer detection and management.

In addition to its impressive pipeline of therapeutic candidates, Oncolys BioPharma Inc. provides a suite of diagnostic drugs and inspection services, supporting cancer diagnosis and monitoring, thereby offering a holistic approach to cancer care and treatment.